All In Biotech

Drug Trial Radar · NCT06512584

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Sep 3, 2024

Primary completion

Sep 28, 2026

Study completion Mar 15, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are: * How effective is PJ009 in treating short bowel syndrome? * Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS. Participants will * Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks, * Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment, * Keep a diary of the amount of their parenteral nutrition/ intravenous fluids (PN/IV), enteral nutrition and urine volume.

Conditions

  • Short Bowel Syndrome

Interventions

  • PJ009Drug

    subcutaneous injections, 0.05 mg/kg once daily

  • PJ009 PlaceboDrug

    subcutaneous injections, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of respondersTime frame: Week 20 to 24 of treatment period

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Chongqing General Hospital

    Chongqing, Chongqing Municipality, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hu'Nan, China

  • General Hospital of Eastern Theater Command

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.